Cell therapy, immuno-oncology, and biotech innovation by Artiva Biotherapeutics
Artiva Biotherapeutics discontinues AlloNK development and reviews strategic alternatives
Artiva Biotherapeutics has announced that it will discontinue development of its AlloNK program and is now evaluating strategic alternatives. The company expressed gratitude to patients, ...
AlloNK plus rituximab delivers clinically meaningful gains in early Sjögren disease study, Artiva Biotherapeutics finds
Artiva Biotherapeutics has announced new clinical data for its AlloNK therapy in combination with rituximab, highlighting mean improvements in disease activity and symptoms at the six-month mark ...
Artiva Biotherapeutics, Inc. early AlloNK plus rituximab results show outpatient potential
Artiva Biotherapeutics, Inc. is advancing efforts to expand access to immune reset therapies through scalable solutions. The company’s investigational AlloNK combined with rituximab produced ...
FDA RMAT designation for AlloNK plus rituximab boosts Artiva Biotherapeutics, Inc. clinical progress
Artiva Biotherapeutics, Inc. announced its financial results for the second quarter of 2026, with ongoing momentum in the development of AlloNK for autoimmune diseases. The company highlighted ...
Artiva Biotherapeutics, Inc. advances AlloNK therapy toward Phase 3 in autoimmune disease
Artiva Biotherapeutics, Inc. announced progress on its AlloNK cell therapy program for autoimmune disease following a recent interview with CEO Fred Aslan. The company discussed new data ...
FDA awards Artiva Biotherapeutics, Inc. RMAT status for AlloNK combination therapy in rheumatoid arthritis
Artiva Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its AlloNK product in combination with ...
Artiva Biotherapeutics aims for first Phase 3 trial targeting B-cell depletion in refractory rheumatoid arthritis
Artiva Biotherapeutics, Inc. has announced a focused strategy to advance its AlloNK therapy as it prepares for its first Phase 3 registrational trial. The company is positioning AlloNK as a ...
Artiva Biotherapeutics, Inc. to outline AlloNK Phase 3 progress at New York Jefferies event
Artiva Biotherapeutics, Inc. will participate in the 2026 Jefferies Global Healthcare Conference in New York, with CEO Fred Aslan, M.D., slated for a fireside chat on Thursday, June 4, from 9:20 ...
Artiva Biotherapeutics, Inc. to present five abstracts on AlloNK at EULAR 2026 across multiple diseases
Artiva Biotherapeutics, Inc. will unveil five accepted abstracts featuring its AlloNK therapeutic at EULAR 2026. These presentations will cover clinical and translational findings across ...
Artiva Biotherapeutics, Inc. to start Phase 3 AlloNK trial in refractory RA after strong early results
Artiva Biotherapeutics, Inc. has announced positive initial clinical results for its AlloNK cell therapy across multiple autoimmune diseases. The company also shared that it reached alignment ...
